Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Epithelial-mesenchymal transitions in development and disease.

Thiery JP, Acloque H, Huang RY, Nieto MA.

Cell. 2009 Nov 25;139(5):871-90. doi: 10.1016/j.cell.2009.11.007. Review.

2.

The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.

Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, Schüler J, Stemmler MP, Herzberger C, Hopt U, Keck T, Brabletz S, Brabletz T.

Nat Cell Biol. 2009 Dec;11(12):1487-95. doi: 10.1038/ncb1998. Epub 2009 Nov 22.

PMID:
19935649
3.

MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells.

Iliopoulos D, Polytarchou C, Hatziapostolou M, Kottakis F, Maroulakou IG, Struhl K, Tsichlis PN.

Sci Signal. 2009 Oct 13;2(92):ra62. doi: 10.1126/scisignal.2000356.

4.

miR-200 enhances mouse breast cancer cell colonization to form distant metastases.

Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J.

PLoS One. 2009 Sep 29;4(9):e7181. doi: 10.1371/journal.pone.0007181.

5.

Causes and consequences of microRNA dysregulation in cancer.

Croce CM.

Nat Rev Genet. 2009 Oct;10(10):704-14. doi: 10.1038/nrg2634. Review.

6.

miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements.

Lal A, Navarro F, Maher CA, Maliszewski LE, Yan N, O'Day E, Chowdhury D, Dykxhoorn DM, Tsai P, Hofmann O, Becker KG, Gorospe M, Hide W, Lieberman J.

Mol Cell. 2009 Sep 11;35(5):610-25. doi: 10.1016/j.molcel.2009.08.020.

7.

p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC.

Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH.

Cell Death Differ. 2010 Feb;17(2):236-45. doi: 10.1038/cdd.2009.109. Epub 2009 Aug 21.

8.

Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines.

Leivonen SK, Mäkelä R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, Enerly E, Aakula A, Hellström K, Sahlberg N, Kristensen VN, Børresen-Dale AL, Saviranta P, Perälä M, Kallioniemi O.

Oncogene. 2009 Nov 5;28(44):3926-36. doi: 10.1038/onc.2009.241. Epub 2009 Aug 17.

PMID:
19684618
9.

Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells.

Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, Diehn M, Liu H, Panula SP, Chiao E, Dirbas FM, Somlo G, Pera RA, Lao K, Clarke MF.

Cell. 2009 Aug 7;138(3):592-603. doi: 10.1016/j.cell.2009.07.011.

10.

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

Baselga J, Swain SM.

Nat Rev Cancer. 2009 Jul;9(7):463-75. doi: 10.1038/nrc2656. Epub 2009 Jun 18. Review.

PMID:
19536107
11.

A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis.

Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA.

Cell. 2009 Jun 12;137(6):1032-46. doi: 10.1016/j.cell.2009.03.047. Retraction in: Cell. 2015 Apr 9;161(2):417.

12.

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT.

Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.

13.

Stable expression of miR-200c alone is sufficient to regulate TCF8 (ZEB1) and restore E-cadherin expression.

Hurteau GJ, Carlson JA, Roos E, Brock GJ.

Cell Cycle. 2009 Jul 1;8(13):2064-9. Epub 2009 Jul 29.

PMID:
19502803
14.

Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.

Qi L, Bart J, Tan LP, Platteel I, Sluis Tv, Huitema S, Harms G, Fu L, Hollema H, Berg Av.

BMC Cancer. 2009 May 28;9:163. doi: 10.1186/1471-2407-9-163.

15.

The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells.

Kato M, Paranjape T, Müller RU, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ.

Oncogene. 2009 Jun 25;28(25):2419-24. doi: 10.1038/onc.2009.106. Epub 2009 May 4. Erratum in: Oncogene. 2009 Aug 20;28(33):3008. Ullrich, R [corrected to Müller, R U].

16.

MicroRNAs and cancer: short RNAs go a long way.

Ventura A, Jacks T.

Cell. 2009 Feb 20;136(4):586-91. doi: 10.1016/j.cell.2009.02.005.

17.

MicroRNAs: target recognition and regulatory functions.

Bartel DP.

Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. Review.

18.

Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7.

Dangi-Garimella S, Yun J, Eves EM, Newman M, Erkeland SJ, Hammond SM, Minn AJ, Rosner MR.

EMBO J. 2009 Feb 18;28(4):347-58. doi: 10.1038/emboj.2008.294. Epub 2009 Jan 15.

19.

miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels.

Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20297-302. doi: 10.1073/pnas.0809376106. Epub 2008 Dec 16.

20.

A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence.

Forman JJ, Legesse-Miller A, Coller HA.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14879-84. doi: 10.1073/pnas.0803230105. Epub 2008 Sep 23.

Supplemental Content

Support Center